Goldman Sachs lowered the firm’s price target on Omada Health (OMDA) to $29 from $33 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with an Equal Weight at Wells Fargo
- Omada announces results from 12-month analysis of GLP-1 companion program
- Omada Health price target lowered to $22 from $29 at Barclays
- Omada Health named Top Pick in Healthcare Technology at Morgan Stanley
- Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach